

^{Pr}Fulphila[®] (pegfilgrastim) injection

Introducing **FULPHILA[®]**, a pegfilgrastim biosimilar to decrease the incidence of infection, as manifested by febrile neutropenia from some cancer treatment(s)¹.




Mylan is committed to improving patient access to high-quality, affordable biological medicines.

Product Information

Product	DIN	Brand Reference
FULPHILA INJ 6 MG/0.6 ML 1PFS	02484153	PrNeulasta [®]


Ordering Information


Product	Pack Size	Mylan Code	UPC
FULPHILA INJ 6 MG/0.6 ML 1PFS	1	400537800	 0 53873 10091 3

For more information contact Mylan Customer Service at 1-800-575-1379

Indication for FULPHILA®

FULPHILA® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.¹

 FULPHILA® is a long-acting form of recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) or filgrastim for subcutaneous injection.¹

 The indication has been granted on the basis of similarity between FULPHILA® and the reference biologic drug Neulasta®* (pegfilgrastim).^{1,2}



Mylan
ADVOCATE®

Providing patient support for FULPHILA®

- Primary point of contact for all Healthcare Professionals and Drug Access Coordinators
- Easy to use portal to enroll patients
- Patient-centric approach to meet patient needs to minimize access barriers

- Reimbursement navigation
- Insurance coverage assistance for public and private drug plans
- Help with necessary paperwork
- Ongoing updates on patient reimbursement status

Additional support for patients:

- Infusion Services
- Ongoing updates on patient infusion status
- Information on FULPHILA® and Biosimilars

Monday to Friday | 8:00 AM to 8:00 PM EST | Phone: 1-833-847-4323 | Fax: 1-833-794-2382
Email: BiosimilarsCanada@innomar-strategies.com | website: www.BiosimilarsCanadaPSP.com

For more information on Mylan's biosimilars go to mylanbiosimilars.ca

For more information about FULPHILA® please visit www.fulphila.ca

References

1. Fulphila (pegfilgrastim) Product Monograph, BGP Pharma ULC. PDF copy available at mylan.ca.
2. Waller CF, Tiessen RJ, Lawrence TE, et al. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol. 2018;144(6):1087-1095.

*Neulasta® is a product of Amgen Canada Inc.

The FULPHILA® Product Monograph is also available upon request by calling 1-844-596-9526.

FULPHILA® is a registered trademark of Mylan Institutional Inc., used under permission by BGP Pharma ULC, a Mylan company.

Mylan® is a registered trademark of Mylan Inc., used under permission by BGP Pharma ULC, a Mylan company.

Copyright© 2019 BGP Pharma ULC, a Mylan company. All rights reserved.

85 Advance Road, Etobicoke, Ontario, M8Z 2S6 M8Z 2S6 | mylan.ca